135 related articles for article (PubMed ID: 16309825)
1. Molecular modeling of new camptothecin analogues to circumvent ABCG2-mediated drug resistance in cancer.
Nakagawa H; Saito H; Ikegami Y; Aida-Hyugaji S; Sawada S; Ishikawa T
Cancer Lett; 2006 Mar; 234(1):81-9. PubMed ID: 16309825
[TBL] [Abstract][Full Text] [Related]
2. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
[TBL] [Abstract][Full Text] [Related]
3. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
4. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
Westover D; Ling X; Lam H; Welch J; Jin C; Gongora C; Del Rio M; Wani M; Li F
Mol Cancer; 2015 Apr; 14():92. PubMed ID: 25928015
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
6. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
Wierdl M; Wall A; Morton CL; Sampath J; Danks MK; Schuetz JD; Potter PM
Mol Pharmacol; 2003 Aug; 64(2):279-88. PubMed ID: 12869632
[TBL] [Abstract][Full Text] [Related]
7. Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Yoshikawa M; Ikegami Y; Sano K; Yoshida H; Mitomo H; Sawada S; Ishikawa T
J Exp Ther Oncol; 2004 Apr; 4(1):25-35. PubMed ID: 15255290
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
9. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Inoue Y; Ikegami Y; Sano K; Suzuki T; Yoshida H; Nakamura Y; Nakagawa H; Ishikawa T
Chemotherapy; 2013; 59(4):260-72. PubMed ID: 24457609
[TBL] [Abstract][Full Text] [Related]
11. The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecan.
Arnaud O; Boumendjel A; Gèze A; Honorat M; Matera EL; Guitton J; Stein WD; Bates SE; Falson P; Dumontet C; Di Pietro A; Payen L
Eur J Cancer; 2011 Mar; 47(4):640-8. PubMed ID: 21216589
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
13. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
[TBL] [Abstract][Full Text] [Related]
14. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
15. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
16. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
[TBL] [Abstract][Full Text] [Related]
17. Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Maliepaard M; van Gastelen MA; Tohgo A; Hausheer FH; van Waardenburg RC; de Jong LA; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2001 Apr; 7(4):935-41. PubMed ID: 11309344
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
19. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
20. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
Takara K; Kitada N; Yoshikawa E; Yamamoto K; Horibe S; Sakaeda T; Nishiguchi K; Ohnishi N; Yokoyama T
Cancer Lett; 2009 Jun; 278(1):88-96. PubMed ID: 19201079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
